User profiles for J. Corvol
jean-christophe corvolSorbonne université, Assistance Publique Hôpitaux de Paris, Inserm, Paris Brain Institute Verified email at aphp.fr Cited by 28015 |
European academy of neurology/movement disorder society‐European section guideline on the treatment of Parkinson's disease: I. Invasive therapies
…, JC Corvol, G Fabbrini, J Ferreira… - European journal of …, 2022 - Wiley Online Library
… J.-C. Corvol received honoraria for talks sponsored by Ever Pharma. J. Ferreira reports
grants from Abbvie, Novartis, Medtronic, and Fundação MSD. He received payment for lectures …
grants from Abbvie, Novartis, Medtronic, and Fundação MSD. He received payment for lectures …
[HTML][HTML] Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects
AM Bonnet, MF Jutras, V Czernecki, JC Corvol… - Parkinson's …, 2012 - hindawi.com
Nonmotor symptoms (NMSs) of Parkinson’s disease (PD) are common, but they are often
underrecognized in clinical practice, because of the lack of spontaneous complaints by the …
underrecognized in clinical practice, because of the lack of spontaneous complaints by the …
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials
JC Corvol, A Bouzamondo, M Sirol… - Archives of internal …, 2003 - jamanetwork.com
Background Previous overviews suggested that hydroxymethyl glutaryl coenzyme A
reductase inhibitors (statins), but not other lipid-lowering therapy (LLT), may reduce stroke …
reductase inhibitors (statins), but not other lipid-lowering therapy (LLT), may reduce stroke …
Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria
…, J Kassubek, JC Corvol, JL Whitwell, J Levin… - Movement …, 2017 - Wiley Online Library
Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria,
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …
Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies
…, M Martinez, JC Corvol, S Lesage, J Jankovic… - The Lancet …, 2019 - thelancet.com
Background Genome-wide association studies (GWAS) in Parkinson's disease have increased
the scope of biological knowledge about the disease over the past decade. We aimed to …
the scope of biological knowledge about the disease over the past decade. We aimed to …
Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum
Many drugs of abuse exert their addictive effects by increasing extracellular dopamine in
the nucleus accumbens, where they likely alter the plasticity of corticostriatal glutamatergic …
the nucleus accumbens, where they likely alter the plasticity of corticostriatal glutamatergic …
Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties
E Valjent, JC Corvol, C Pagès, MJ Besson… - Journal of …, 2000 - Soc Neuroscience
A central feature of drugs of abuse is to induce gene expression in discrete brain structures
that are critically involved in behavioral responses related to addictive processes. Although …
that are critically involved in behavioral responses related to addictive processes. Although …
Targeting chelatable iron as a therapeutic modality in Parkinson's disease
…, N Zahr, A Destée, JC Corvol… - Antioxidants & redox …, 2014 - liebertpub.com
Aims: The pathophysiological role of iron in Parkinson's disease (PD) was assessed by a
chelation strategy aimed at reducing oxidative damage associated with regional iron …
chelation strategy aimed at reducing oxidative damage associated with regional iron …
[PDF][PDF] Loss of VPS13C function in autosomal-recessive parkinsonism causes mitochondrial dysfunction and increases PINK1/Parkin-dependent mitophagy
…, F Tison, C Tranchant, M Vidailhet, JC Corvol… - The American Journal of …, 2016 - cell.com
Autosomal-recessive early-onset parkinsonism is clinically and genetically heterogeneous.
The genetic causes of approximately 50% of autosomal-recessive early-onset forms of …
The genetic causes of approximately 50% of autosomal-recessive early-onset forms of …
[HTML][HTML] Trial of deferiprone in Parkinson's disease
Background Iron content is increased in the substantia nigra of persons with Parkinson’s
disease and may contribute to the pathophysiology of the disorder. Early research suggests that …
disease and may contribute to the pathophysiology of the disorder. Early research suggests that …